Cite
HARVARD Citation
Cingolani, A. et al. (n.d.). P398 Long term efficacy and safety of ABP, 501 adalimumab biosimilar in inflammatory bowel diseases: preliminary results from the ADASWITCH study. Journal of Crohn's and colitis. pp. i392-i393. [Online].